Skip to main navigation
Skip to search
Skip to main content
University of Arizona Home
Home
Profiles
Departments and Centers
Scholarly Works
Activities
Grants
Datasets
Prizes
Search by expertise, name or affiliation
Pharmacoeconomics of amifostine in ovarian cancer
E. A. Calhoun, C. L. Bennett
Community, Environment and Policy
Research output
:
Contribution to journal
›
Article
›
peer-review
13
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Pharmacoeconomics of amifostine in ovarian cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Ovarian Cancer
100%
Amifostine
100%
Health Care Cost
85%
Quality of Life
14%
Radiation Therapy
14%
Malignant Neoplasm
14%
Nephrotoxicity
14%
Oncology
14%
Neutropenia
14%
Thrombocytopenia
14%
Chronic Disease
14%
Combination Therapy
14%
Peripheral Neuropathy
14%
Cost Benefit Analysis
14%
Mucositis
14%
Xerostomia
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Pharmacoeconomics
100%
Amifostine
100%
Chemotherapy
28%
Malignant Neoplasm
14%
Nephrotoxicity
14%
Combination Therapy
14%
Chronic Disease
14%
Thrombocytopenia
14%
Neutropenia
14%
Peripheral Neuropathy
14%
Mucosa Inflammation
14%
Xerostomia
14%
Keyphrases
Radiotherapy-induced
16%
Cost-effective Framework
16%